title: Constitutive knockout of kalirin-7 leads to increased rates of cocaine self-administration.
abstract: Kalirin-7 (Kal7) is a Rho-guanine nucleotide exchange factor that is localized in neuronal postsynaptic densities. Kal7 interacts with the NR2B subunit of the NMDA receptor and regulates aspects of dendritic spine dynamics both in vitro and in vivo. Chronic treatment with cocaine increases dendritic spine density in the nucleus accumbens (NAc) of rodents and primates. Kal7 mRNA and protein are upregulated in the NAc following cocaine treatment, and the presence of Kal7 is necessary for the normal proliferation of dendritic spines following cocaine use. Mice that constitutively lack Kal7 [Kalirin-7 knockout mice (Kal7(KO))] demonstrate increased locomotor sensitization to cocaine and a decreased place preference for cocaine. Here, using an intravenous cocaine self-administration paradigm, Kal7(KO) mice exhibit increased administration of cocaine at lower doses as compared with wild-type (Wt) mice. Analyses of mRNA transcript levels from the NAc of mice that self-administered saline or cocaine reveal that larger splice variants of the Kalrn gene are increased by cocaine more dramatically in Kal7(KO) mice than in Wt mice. Additionally, transcripts encoding the NR2B subunit of the NMDA receptor increased in Wt mice that self-administered cocaine but were unchanged in similarly experienced Kal7(KO) mice. These findings suggest that Kal7 participates in the reinforcing effects of cocaine, and that Kal7 and cocaine interact to alter the expression of genes related to critical glutamatergic signaling pathways in the NAc.
authors.affiliation: Department of Neuroscience, University of Connecticut Health Center, Farmington, Connecticut (D.D.K., T.P.L., B.A.E., R.E.M.); and Department of Psychology, Program in Behavioral Neuroscience (N.E.N., S.E.T., S.L.Y., M.F.O.) and Interdisciplinary Graduate Program in Neuroscience (M.F.O.), Arizona State University, Tempe, Arizona.
authors.forename: Drew D
authors.initials: DD
authors.lastname: Kiraly
authors.forename: Natali E
authors.initials: NE
authors.lastname: Nemirovsky
authors.forename: Taylor P
authors.initials: TP
authors.lastname: LaRese
authors.forename: Seven E
authors.initials: SE
authors.lastname: Tomek
authors.forename: Stephanie L
authors.initials: SL
authors.lastname: Yahn
authors.forename: M Foster
authors.initials: MF
authors.lastname: Olive
authors.forename: Betty A
authors.initials: BA
authors.lastname: Eipper
authors.forename: Richard E
authors.initials: RE
authors.lastname: Mains
mesh_terms: D000818:Animals; D016739:Behavior, Addictive / Q000235:genetics / Q000378:metabolism* / Q000523:psychology; D003042:Cocaine / Q000008:administration & dosage*; D020662:Guanine Nucleotide Exchange Factors / Q000172:deficiency* / Q000235:genetics*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D012646:Self Administration; D015854:Up-Regulation / Q000235:genetics*
chemical_list: D020662:Guanine Nucleotide Exchange Factors; C548820:KALRN protein, mouse; D003042:Cocaine
references.citation: Behav Genet. 2007 Jan;37(1):101-18
references.pmid: 17226102
references.citation: BMC Neurosci. 2011 Dec 19;12:126
references.pmid: 22182308
references.citation: Biol Psychiatry. 2010 Aug 1;68(3):249-55
references.pmid: 20452575
references.citation: Neuron. 2009 Jul 16;63(1):40-7
references.pmid: 19607791
references.citation: J Neurosci. 2008 Nov 19;28(47):12368-82
references.pmid: 19020030
references.citation: ScientificWorldJournal. 2012;2012:939584
references.pmid: 23365539
references.citation: Biol Psychiatry. 2011 Feb 1;69(3):218-27
references.pmid: 21055728
references.citation: Curr Opin Pharmacol. 2009 Feb;9(1):59-64
references.pmid: 19157986
references.citation: J Neurosci. 2011 Jun 1;31(22):8163-74
references.pmid: 21632938
references.citation: Nat Neurosci. 2009 May;12(5):602-10
references.pmid: 19349975
references.citation: Epigenetics. 2011 Sep 1;6(9):1095-104
references.pmid: 21814037
references.citation: Neuropsychopharmacology. 2011 Nov;36(12):2422-30
references.pmid: 21849985
references.citation: Mol Pharmacol. 2005 Jun;67(6):2126-36
references.pmid: 15774772
references.citation: Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3399-404
references.pmid: 16492766
references.citation: Neuron. 2010 Jun 24;66(6):859-70
references.pmid: 20620872
references.citation: Neuropharmacology. 2011 Dec;61(7):1060-9
references.pmid: 21232547
references.citation: Annu Rev Neurosci. 2006;29:565-98
references.pmid: 16776597
references.citation: Curr Neurol Neurosci Rep. 2010 May;10(3):207-14
references.pmid: 20425036
references.citation: J Psychiatr Res. 2012 May;46(5):635-43
references.pmid: 22364833
references.citation: Neuron. 2008 Aug 28;59(4):621-33
references.pmid: 18760698
references.citation: J Neurosci. 1997 Nov 1;17(21):8491-7
references.pmid: 9334421
references.citation: J Neurosci. 2007 Nov 21;27(47):12967-76
references.pmid: 18032670
references.citation: Neuropsychopharmacology. 2010 Jan;35(1):217-38
references.pmid: 19710631
references.citation: Annu Rev Neurosci. 2010;33:349-78
references.pmid: 20367247
references.citation: Mol Psychiatry. 2002;7(10):1101-6
references.pmid: 12476325
references.citation: Synapse. 2001 Mar 1;39(3):257-66
references.pmid: 11169774
references.citation: Trends Neurosci. 2010 Jun;33(6):267-76
references.pmid: 20207024
references.citation: Eur J Pharmacol. 2005 Dec 5;526(1-3):65-76
references.pmid: 16321382
references.citation: Nat Neurosci. 2010 Sep;13(9):1137-43
references.pmid: 20729844
references.citation: Nat Rev Neurosci. 2009 Aug;10(8):561-72
references.pmid: 19571793
references.citation: Nat Neurosci. 2005 Nov;8(11):1445-9
references.pmid: 16251986
references.citation: Psychiatr Clin North Am. 2012 Jun;35(2):495-519
references.pmid: 22640768
references.citation: J Neurosci. 2002 May 1;22(9):3306-11
references.pmid: 11978804
references.citation: Prog Neurobiol. 2011 Sep 15;95(1):1-13
references.pmid: 21704115
references.citation: Neurochem Res. 2011 Mar;36(3):383-91
references.pmid: 21152977
references.citation: J Neurosci. 2008 Jan 16;28(3):711-24
references.pmid: 18199770
references.citation: BMC Neurosci. 2011 Feb 17;12:20
references.pmid: 21329509
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18561-6
references.pmid: 19017804
references.citation: Mol Pharmacol. 2012 Oct;82(4):738-45
references.pmid: 22828798
references.citation: Psychopharmacology (Berl). 2006 Nov;189(1):1-16
references.pmid: 17019567
references.citation: J Neurosci. 2003 Nov 19;23(33):10593-603
references.pmid: 14627644
references.citation: Neuropsychopharmacology. 2013 Mar;38(4):628-38
references.pmid: 23169347
references.citation: Science. 2004 Aug 13;305(5686):1014-7
references.pmid: 15310906
references.citation: Front Neural Circuits. 2013 Feb 19;7:22
references.pmid: 23423476
references.citation: Nat Rev Neurosci. 2007 Nov;8(11):844-58
references.pmid: 17948030
references.citation: Brain Res. 2010 Jan 14;1309:83-94
references.pmid: 19896929
references.citation: J Comp Neurol. 2001 Jan 15;429(3):388-402
references.pmid: 11116227
references.citation: Curr Protoc Neurosci. 2005 Aug;Chapter 9:Unit 9.20
references.pmid: 18428629
references.citation: Curr Opin Neurobiol. 2013 Aug;23(4):507-12
references.pmid: 23428655
references.citation: ACS Chem Neurosci. 2010 May 19;1(5):348-365
references.pmid: 20543890
references.citation: Nat Neurosci. 2012 Oct;15(10):1382-90
references.pmid: 22960932
references.citation: Exp Neurol. 2006 Aug;200(2):343-55
references.pmid: 16631172
references.citation: Mol Pharmacol. 2005 Jun;67(6):2115-25
references.pmid: 15755907
references.citation: J Neurosci. 2011 Aug 31;31(35):12554-65
references.pmid: 21880917
references.citation: J Neurosci. 2002 Aug 15;22(16):6980-90
references.pmid: 12177196
references.citation: Genes Brain Behav. 2013 Feb;12(1):21-33
references.pmid: 23094851
references.citation: Annu Rev Pharmacol Toxicol. 1999;39:221-41
references.pmid: 10331083
references.citation: Neuroscience. 2003;116(1):19-22
references.pmid: 12535933